| pubmed-article:10973037 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10973037 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10973037 | lifeskim:mentions | umls-concept:C0010674 | lld:lifeskim |
| pubmed-article:10973037 | lifeskim:mentions | umls-concept:C0024128 | lld:lifeskim |
| pubmed-article:10973037 | lifeskim:mentions | umls-concept:C1561566 | lld:lifeskim |
| pubmed-article:10973037 | lifeskim:mentions | umls-concept:C0034927 | lld:lifeskim |
| pubmed-article:10973037 | lifeskim:mentions | umls-concept:C0302614 | lld:lifeskim |
| pubmed-article:10973037 | lifeskim:mentions | umls-concept:C1706050 | lld:lifeskim |
| pubmed-article:10973037 | lifeskim:mentions | umls-concept:C0181090 | lld:lifeskim |
| pubmed-article:10973037 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:10973037 | pubmed:dateCreated | 2000-10-26 | lld:pubmed |
| pubmed-article:10973037 | pubmed:abstractText | Forced expiratory volume in one second (FEV(1)) is widely used to guide referral of patients with cystic fibrosis (CF) for lung transplantation. We reasoned that the best FEV(1) in a 6-month period (bFEV(1)) would be a useful marker of the need for transplant referral. We examined both the rate of decline and different threshold values of bFEV(1) as prognostic indicators in young CF patients. In a case-control analysis, rates of decline in and threshold values of bFEV(1) of 28 patients dying between ages 7-18 years from 1980-1997 were compared to those of 28 age- and gender-matched controls. The threshold analysis of bFEV(1) values was then applied to all patients under age 19 years followed in our clinic from 1993-1997. The rate of decline in bFEV(1) differed for cases and controls over the 4-year period prior to death, but not from years 2-4 prior to death, the time at which transplant referral decisions should be made. A bFEV(1) value of 50% predicted at 2 years prior to the death of the case selected 14 of 28 cases and one control. When applied to all pediatric patients followed from 1993-1997, a bFEV1 threshold of 50% predicted selected 2 of the 3 patients who died and 3 of the 140 patients who survived. Consideration of lung transplantation referral should begin when young CF patients have a best FEV(1) <50% predicted despite aggressive conventional treatment. | lld:pubmed |
| pubmed-article:10973037 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10973037 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10973037 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10973037 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10973037 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10973037 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10973037 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:10973037 | pubmed:issn | 8755-6863 | lld:pubmed |
| pubmed-article:10973037 | pubmed:author | pubmed-author:RobinsonWW | lld:pubmed |
| pubmed-article:10973037 | pubmed:author | pubmed-author:WaltzD ADA | lld:pubmed |
| pubmed-article:10973037 | pubmed:copyrightInfo | Copyright 2000 Wiley-Liss, Inc. | lld:pubmed |
| pubmed-article:10973037 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10973037 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:10973037 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10973037 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10973037 | pubmed:pagination | 198-202 | lld:pubmed |
| pubmed-article:10973037 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:10973037 | pubmed:meshHeading | pubmed-meshheading:10973037... | lld:pubmed |
| pubmed-article:10973037 | pubmed:meshHeading | pubmed-meshheading:10973037... | lld:pubmed |
| pubmed-article:10973037 | pubmed:meshHeading | pubmed-meshheading:10973037... | lld:pubmed |
| pubmed-article:10973037 | pubmed:meshHeading | pubmed-meshheading:10973037... | lld:pubmed |
| pubmed-article:10973037 | pubmed:meshHeading | pubmed-meshheading:10973037... | lld:pubmed |
| pubmed-article:10973037 | pubmed:meshHeading | pubmed-meshheading:10973037... | lld:pubmed |
| pubmed-article:10973037 | pubmed:meshHeading | pubmed-meshheading:10973037... | lld:pubmed |
| pubmed-article:10973037 | pubmed:meshHeading | pubmed-meshheading:10973037... | lld:pubmed |
| pubmed-article:10973037 | pubmed:meshHeading | pubmed-meshheading:10973037... | lld:pubmed |
| pubmed-article:10973037 | pubmed:meshHeading | pubmed-meshheading:10973037... | lld:pubmed |
| pubmed-article:10973037 | pubmed:meshHeading | pubmed-meshheading:10973037... | lld:pubmed |
| pubmed-article:10973037 | pubmed:meshHeading | pubmed-meshheading:10973037... | lld:pubmed |
| pubmed-article:10973037 | pubmed:meshHeading | pubmed-meshheading:10973037... | lld:pubmed |
| pubmed-article:10973037 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10973037 | pubmed:articleTitle | FEV(1) as a guide to lung transplant referral in young patients with cystic fibrosis. | lld:pubmed |
| pubmed-article:10973037 | pubmed:affiliation | Division of Respiratory Diseases, Children's Hospital, Boston, Massachusetts 02115, USA. | lld:pubmed |
| pubmed-article:10973037 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10973037 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:10973037 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10973037 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10973037 | lld:pubmed |
